FIELD: pharmaceutics.
SUBSTANCE: present invention refers to pharmaceutics, namely to a method of treating refractory celiac disease in a subject. Method of treating refractory celiac disease in a subject, comprising administering to the subject a tolerance-inducing immunomodifying particle (TIMP) encapsulating one or more antigenic epitopes of gliadin (GLIA), where TIMP-GLIA is administered in dose of 0.1 to 10 mg/kg, where the subject has a genetic profile HLA-DQ2.5 (HLA-DQA1*0501/B1*0201) or HLA-DQ8.1 (DQA1*0301/B1*0302).
EFFECT: invention enables treating refractory celiac disease using TIMP-GLIA.
14 cl, 12 dwg, 9 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| METHOD FOR INCREASING NUMBER OF LYMPHOCYTES IN TUMOURS USING HYBRID PROTEIN IL-7 | 2020 |
|
RU2822396C1 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
| FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE | 2019 |
|
RU2811541C2 |
| COMPOSITIONS OF ANTI-CD6 ANTIBODIES AND METHODS OF TREATING AND REDUCING NEGATIVE CONSEQUENCES OF CORONAVIRUS, INCLUDING COVID-19 | 2021 |
|
RU2828013C1 |
| ANTIBODIES, THEIR APPLICATION AND METHODS OF APPLICATION | 2016 |
|
RU2725221C2 |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
| DOSING STRATEGY REDUCING CYTOKINE RELEASE SYNDROME FOR CD3/C20 BISPECIFIC ANTIBODIES | 2019 |
|
RU2799529C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
